Testing how safe and tolerable a new drug is for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older when you sign the consent form
- Have a confirmed blood or lymph cancer that has relapsed or is refractory (not responding) and you have tried all available standard options
- Have measurable or evaluable disease (doctors can track it)
- Be able to do daily activities fairly well, with an ECOG score of 2 or less
- Use effective birth control or an approved way to avoid pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SCTC21C, for people with certain blood cancers (like myeloma or lymphoma) that have come back or not responded to other treatments. The goal is to see if the drug is safe and can help control the cancer.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
This early Phase 1 study tests OT-A201 (a first-time-in-humans drug) in people with certain relapsed or advanced cancers. It helps doctors learn the safest dose and how the treatment may work for cancers that have already been treated.
This trial tests a new drug called Romiplostim N01 to see if it works better than the standard treatment (recombinant human thrombopoietin) for raising low platelets caused by cancer therapies, when other treatments have failed. It is for people aged 18-75 with solid tumors or blood cancers who have not responded to at least two platelet growth factors.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
This early-stage trial tests a new drug called HRS-1635 in patients with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to previous treatment. The goal is to find the right dose and understand how well and safely the drug works.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.